Investor Ligand Pharmaceuticals Inc
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Ligand Pharmaceuticals Inc . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2026-05-01 13D XOMAO / XOMA Royalty Corporation - Preferred Stock 8,062,678
2025-11-10 13D/A PTHS / Pelthos Therapeutics Inc. 4,927,868 5,189,177
2025-07-03 13D PTHS / Pelthos Therapeutics Inc. 4,927,868
2023-03-30 13D/A VKTX / Viking Therapeutics, Inc. 6,065,080 3,616,077
2023-02-09 13D/A VKTX / Viking Therapeutics, Inc. 7,339,383 6,065,080
2021-01-15 13G/A SEEL / Seelos Therapeutics, Inc. 2,224,000 2,224,000
2020-08-28 13D/A VKTX / Viking Therapeutics, Inc. 7,558,083 7,339,383
2020-02-12 13G/A SEEL / Seelos Therapeutics, Inc. 2,224,000 2,224,000
2019-04-15 13G SEEL / Seelos Therapeutics, Inc. 2,224,000
2018-11-13 13D/A VKTX / Viking Therapeutics, Inc. 7,820,964 7,558,083
2016-04-15 13D/A VKTX / Viking Therapeutics, Inc. 4,780,964 7,820,964
2015-06-01 13D/A VKTX / Viking Therapeutics, Inc. 4,552,859 4,780,964
2015-05-08 13D VKTX / Viking Therapeutics, Inc. 4,552,859
2013-01-11 13G TVTX / Travere Therapeutics, Inc. 620,000